Theragenics Corporation

Theragenics Corporation is a global specialty medical device company founded in 1981 by physicists from Georgia Institute of Technology, headquartered in Buford, Georgia. The company specializes in commercial-scale radioisotope manufacturing and low-dose-rate (LDR) brachytherapy seeds for cancer treatment, with a vertically integrated operation managing isotope production, manufacturing, and global logistics. Theragenics operates a 134,000 sq ft radioisotope production facility with 14 cyclotrons enabling large-scale isotope production for therapeutic and diagnostic radiopharmaceuticals. The company's flagship brachytherapy products include TheraSeed® Palladium-103, AgX100® Iodine-125, and Cesium-131 seeds, along with innovative delivery systems such as preloaded needle trays, eye plaques, C20™ cartridges, AnchorSeed® encapsulated seeds, and stranded configurations. Theragenics also provides contract manufacturing services for radiopharmaceuticals and operates subsidiary companies offering interventional radiology and vascular surgery solutions. With over 40 years of excellence, the company has treated more than 271,000 patients worldwide and serves physicians and providers in over 40 countries, emphasizing precision, quality, and patient-centric innovation in minimally invasive cancer therapies.